What is Kanvas Biosciences?
Kanvas Biosciences is a pioneering spatial biology enterprise dedicated to revolutionizing the treatment of microbiome-associated diseases. The company has engineered the world's first platform capable of comprehensive microbiome drug screening, discovery, and manufacturing. By integrating advanced spatial mapping of the microbiome with precise host gene expression profiling, Kanvas enables the development of complex live biotherapeutic consortia. Originally spun out of Cornell University, the firm is uniquely positioned to address unmet clinical needs by restoring microbiome health through highly engineered, multi-member therapeutic solutions.
How much funding has Kanvas Biosciences raised?
Kanvas Biosciences has raised a total of $76.4M across 3 funding rounds:
Other Financing Round
$3.9M
Seed
$24.5M
Series A
$48M
Other Financing Round (2024): $3.9M with participation from Lions Capital Mortgage, Uncommon Denominator, and DCVC
Seed (2024): $24.5M led by DCVC, Lions Capital Mortgage, Germin8, FemHealth Ventures, Cooke, and Uncommon Denominator
Series A (2026): $48M supported by Cornell University, Alumni Ventures, FemHealth Ventures, Germin8 Ventures, Bill & Melinda Gates Foundation, Triple Impact Capital, DCVC Management, Uncommon Denominator, Mana Ventures, Kicker Ventures, Pangaea Ventures, Gaingels, Boutique Venture Partners, and Rochester Institute of Technology
Key Investors in Kanvas Biosciences
DCVC Management
A deep tech venture capital firm that leverages artificial intelligence to solve complex challenges across biotechnology, energy, and agriculture sectors.
Bill & Melinda Gates Foundation
A global philanthropic organization focused on supporting individuals experiencing extreme poverty and hunger to lead healthier, more productive lives.
Pangaea Ventures
A specialized venture capital firm focusing on hard tech and industrial transformation through advancements in materials, chemistry, and biology.
What's next for Kanvas Biosciences?
With the successful closure of its Series A round, Kanvas Biosciences is set to scale its manufacturing capabilities and expand its clinical pipeline. The strategic focus will shift toward validating its drug discovery platform in human-centric models and deepening its intellectual property moat. As the company matures, it will likely prioritize partnerships with global health organizations and pharmaceutical entities to translate its spatial biology insights into scalable, next-generation therapies that address systemic health challenges.
See full Kanvas Biosciences company page
